Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1006930 | 1.00 | GPR84 (0.45) | GPR84FFAR1FFAR4LMNAALDH1A1 | |
| SCHEMBL1006439 | 1.00 | — | — | |
| SCHEMBL329265 | 1.00 | — | — | |
| SCHEMBL3028793 | 1.00 | GPR84 (0.45) | GPR84FFAR1FFAR4LMNAALDH1A1 | |
| SCHEMBL1007247 | 1.00 | GPR84 (0.45) | GPR84FFAR1FFAR4LMNAALDH1A1 | |
| SCHEMBL1008160 | 1.00 | GPR84 (0.45) | GPR84FFAR1FFAR4LMNAALDH1A1 | |
| SCHEMBL1007034 | 1.00 | GPR84 (0.45) | GPR84FFAR1FFAR4LMNAALDH1A1 | |
| SCHEMBL1006956 | 1.00 | GPR84 (0.45) | GPR84FFAR1FFAR4LMNAALDH1A1 | |
| SCHEMBL1007009 | 1.00 | GPR84 (0.45) | GPR84FFAR1FFAR4LMNAALDH1A1 | |
| SCHEMBL1006246 | 1.00 | GPR84 (0.45) | GPR84FFAR1FFAR4LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0666847-B1 | TRYPTAMINE ANALOGS WITH 5-HT1D SELECTIVITY | ALLELIX BIOPHARMA (CA) | 1998-06-17 | — | — | EP | claimed |
| US-5496957-A | 5-HYDOXYTRYPTAMINE | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1996-03-05 | — | — | US | claimed |
| EP-0666847-A1 | TRYPTAMINE ANALOGS WITH 5-HT1D SELECTIVITY | Allelix Biopharmaceuticals Inc. (CA) | 1995-08-16 | — | — | EP | claimed |
| WO-1995006638-A1 | TRYPTAMINE ANALOGS WITH 5-HT1D SELECTIVITY | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1995-03-09 | — | — | WO | claimed |
| CN-105611920-B | Preparation of hydroxy-diphenylmethane derivatives | 泰拉科斯萨普有限责任公司 | 2021-07-16 | — | — | CN | disclosed |
| EP-3055281-B1 | PREPARATION OF HYDROXY-BENZYLBENZENE DERIVATIVES | THERACOS SUB LLC (US) | 2020-01-08 | — | — | EP | disclosed |
| US-10093616-B2 | Preparation of hydroxy-benzylbenzene derivatives | THERACOS SUB, LLC (US) | 2018-10-09 | — | — | US | disclosed |
| US-9725478-B2 | Process for the preparation of benzylbenzene SGLT2 inhibitors | THERACOS SUB, LLC (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160355471-A1 | PREPARATION OF HYDROXY-BENZYLBENZENE DERIVATIVES | THERACOSBIO, LLC | 2016-12-08 | — | — | US | disclosed |
| US-9464043-B2 | Preparation of hydroxy-benzylbenzene derivatives | THERACOS SUB, LLC (US) | 2016-10-11 | — | — | US | disclosed |
| EP-3055281-A1 | PREPARATION OF HYDROXY-BENZYLBENZENE DERIVATIVES | Theracos Sub, LLC (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20160207952-A1 | PROCESS FOR THE PREPARATION OF BENZYLBENZENE SGLT2 INHIBITORS | THERACOSBIO, LLC | 2016-07-21 | — | — | US | disclosed |
| EP-0519423-A2 | Phthalocyanine compounds and usage thereof | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1992-12-23 | — | — | EP | disclosed |
| US-5053548-A | Containing hydroxy substituents; nervous system disorders | OTSUKA PHARMACEUTICAL COMPANY, LTD. (JP) | 1991-10-01 | — | — | US | disclosed |
| EP-0382213-A2 | Biphenyl derivative, nerve cell degeneration repairing or protecting agent and process for preparing a phenyl derivative contained in the agent | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-16 | — | — | EP | disclosed |
| EP-0382185-A2 | Carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-16 | — | — | EP | disclosed |
| US-4496447-A | PHOTOPOLYMERIZATION OF UNSATURATED COMPOUNDS AND FOR CURING PRINTING INKS | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1985-01-29 | — | — | US | disclosed |
| US-4450307-A | Hydroxy-containing bicycloalkane ether compounds | TEXACO INC. (US) | 1984-05-22 | — | — | US | disclosed |
| US-4374984-A | Aromatic-aliphatic ketones useful as photoinitiators | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1983-02-22 | — | — | US | disclosed |
| US-4160020-A | CELLULOSE ESTERS, CELLULOSE ETHERS | ALZA CORPORATION (US) | 1979-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207952-A1 | PROCESS FOR THE PREPARATION OF BENZYLBENZENE SGLT2 INHIBITORS | SLC5A2, SLC5A1, SLC2A4 | GPR84 929/4885FFAR1 824/4885FFAR4 522/4885 |
| US-20160355471-A1 | PREPARATION OF HYDROXY-BENZYLBENZENE DERIVATIVES | SLC5A2, SLC5A1, SLC2A8 | GPR84 1335/4885FFAR1 366/4885FFAR4 207/4885 |
| US-10093616-B2 | Preparation of hydroxy-benzylbenzene derivatives | SLC5A2, SLC5A1, SLC2A8 | GPR84 1335/4885FFAR1 366/4885FFAR4 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.